title: Effect of bevacizumab treatment on p-boronophenylalanine distribution in murine tumor.
abstract: Previous studies have demonstrated that angiogenesis inhibitors can enhance tumor inhibitory effects of chemo- and radiotherapy via their action on tumor vessels. Here, we studied the effect of the angiogenesis inhibitor, bevacizumab (Avastin), on boron distribution in a murine tumor model. The human head and neck squamous cell carcinoma cell line was used for inoculation into mice. Boron-10 concentrations in tissues were measured by prompt γ-ray spectrometry (PGA). Hoechst 33342 perfusion and p-boronophenylalanine (BPA) distribution were determined by immunofluorescence staining. Our results revealed enhanced tumor blood perfusion and BPA accumulation in tumors after Avastin treatment, suggesting that combination of angiogenesis inhibition with treatment with boron compound administration may improve the efficacy of boron neutron capture therapy (BNCT) by modifying tumor vessels. In addition, our results also demonstrated the usefulness of immunofluorescence staining for investigating boron compound distribution at the cellular level.
authors.affiliation: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Liu
authors.forename: Minoru
authors.initials: M
authors.lastname: Suzuki
authors.forename: Shin-Ichiro
authors.initials: S
authors.lastname: Masunaga
authors.forename: Yi-Wei
authors.initials: YW
authors.lastname: Chen
authors.forename: Genro
authors.initials: G
authors.lastname: Kashino
authors.forename: Hiroki
authors.initials: H
authors.lastname: Tanaka
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Sakurai
authors.forename: Mitsunori
authors.initials: M
authors.lastname: Kirihata
authors.forename: Koji
authors.initials: K
authors.lastname: Ono
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D001896:Boron Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D016754:Boron Neutron Capture Therapy / Q000379:methods*; D045744:Cell Line, Tumor; D004347:Drug Interactions; D005260:Female; D006258:Head and Neck Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D008657:Metabolic Clearance Rate / Q000528:radiation effects; D051379:Mice; D008807:Mice, Inbred BALB C; D010649:Phenylalanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D014018:Tissue Distribution / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D001896:Boron Compounds; D011838:Radiation-Sensitizing Agents; D000068258:Bevacizumab; D010649:Phenylalanine; C033685:4-boronophenylalanine